Our Firm’s attorneys are currently representing numerous women who allege injuries caused by implants manufactured by C.R. Bard, Ethicon and several other companies.
New York, NY (PRWEB) January 19, 2015
More than 9,000 transvaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) are now pending in New Jersey Superior Court after being filed by women who were allegedly injured by implants manufactured by C.R. Bard Inc. and the Johnson & Johnson subsidiary, Ethicon, Bernstein Liebhard LLP reports.
According to Case Lists updated on January 3rd, more than 7,400 claims are now centralized in the Bergen County litigation established for claims involving Ethicon mesh devices, while another 1,630 have been filed in the C.R. Bard proceeding. These cases allege similar injuries caused by transvaginal mesh implants that were designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Women involved in the New Jersey lawsuits accuse both companies of failing to adequately warn about risks associated with their products. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)
“We are pleased to see continued progress in the New Jersey litigations that currently include thousands of transvaginal mesh lawsuits, as our Firm’s attorneys are currently representing numerous women who allege injuries caused by implants manufactured by C.R. Bard, Ethicon and several other companies,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free and confidential case evaluations to women who may have been harmed by products manufactured by C.R. Bard, Johnson & Johnson’s Ethicon unit, American Medical Systems and Boston Scientific Corp.
Transvaginal Mesh Lawsuits
According to court documents, the nationwide transvaginal mesh litigation has continued to mount since 2008, when the U.S. Food and Drug Administration (FDA) issued its first public health alert that warned about the risk for vaginal mesh complications. The federal regulator categorized the potential for them to occur as “rare,” a position it augmented three years later after receiving 3,000 adverse event reports from women who alleged mesh erosion and other injuries caused by pelvic implants they received. Following these revelations, the FDA referred to the risk as “not rare” in a notice issued in July 2011.
Three years later, the FDA took its most recent step in addressing problems with transvaginal mesh by proposing new regulations that would classify the devices as “high risk.” This would require that manufacturers submit them for rigorous safety testing prior to receiving market approval.*
Jeffrey S. Grand, a partner at Bernstein Liebhard LLP, is currently serving as Co-Liaison Counsel for both the C.R. Bard and Ethicon transvaginal mesh litigations in New Jersey. For the Ethicon litigation, Mr. Grand also served on the Plaintiff’s trial team for a case that concluded in March 2013 with an $11 million ruling in favor of a woman whose Gynecare Prolift implant was found to have caused her injuries.
Mr. Grand is also serving on the Plaintiffs’ Steering Committees in the following seven separate multidistrict litigations underway in the U.S. District Court, Southern District of West Virginia: (In Re: C.R. Bard, Inc., Pelvic Repair System Products Liability Litigation - MDL No. 2187; In Re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation - MDL No. 2325; In Re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation - MDL No. 2326; In re: Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation - MDL No. 2327; Coloplast Corp. Pelvic Support Systems Products Liability Litigation - MDL No. 2387; In Re: Cook Medical, Inc., Pelvic Repair System Products Liability Litigation - MDL No. 2440; and In Re: Neomedic Pelvic Repair System Products Liability Litigation - MDL No. 2511.)
Women who allege serious complications of transvaginal mesh may be eligible to receive compensation for lost wages, medical bills, pain and suffering and other injury-related damages. Learn more about filing a lawsuit through a transvaginal mesh attorney at Bernstein Liebhard LLP by visiting the Firm’s website, or Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395192.htm, U.S. Food and Drug Administration (FDA), April 29, 2014.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP